NCT04537286View on ClinicalTrials.gov

First-line Nab-paclitaxel Plus Cisplatin Plus Carilizumab in mTNBC Patients

PHASE2RecruitingINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

August 25, 2020

Primary Completion Date

September 15, 2024

Study Completion Date

October 15, 2024

Conditions
Breast Cancer
Interventions
DRUG

nab-paclitaxel plus cisplatin plus carilizumab (AP+PD-1)

Nab-paclitaxel 125 mg/m2，ivgtt，d1, 8 Cisplatin 75 mg/m2，ivgtt，d1 Carilizumab 200mg, ivgtt，d1，q2w

Trial Locations (1)

200032

RECRUITING

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors
lead

Fudan University

OTHER